The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
A study led by researchers from the Clínic-IDIBAPS paves the way for the design and optimization of CAR T-cell therapy for greater effectiveness in t1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
The University of Pennsylvania professor and pioneer in developing cancer therapies using T cells covered the history, current state, and future chal1
The researchers’ goal is to develop a method to reverse the exhaustion that affects T-cells during protracted battles with tumor cells, preventing th1
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
